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Contributing factors to the inhibition of phagocytosis in hemodialyzed
patients. Although polymorphonuclear (PMNL) glucose consumption
as an index of metabolic response to phagocytosis in the production of
free radical species is depressed in hemodialyzed patients, substantial
interindividual differences are registered. Studies evaluating to what
variables these differences are related are, however, lacking. In the
present study, the relation of several factors to PMNL functional
capacity in the breakdown of glucose to CO2 by the hexose monophos-
phate shunt (HMS) is considered in an individual and multifactorial
regression analysis. Starting from a database, collected in 126 stabilized
hemodialysis patients, PMNL HMS-response to standard quantities of
latex and zymosan was correlated to 14 numerical parameters: time
since the start of dialysis, hematocrit, serum creatinine, phosphorus,
ferritin, albumin, parathormone, albumin before and after administra-
tion of desferrioxamine, residual creatinine clearance, PCR, TAC,,rC,,,
KtJV and age. In addition, the non-numeric parameters of sex, biocom-
patibility of dialyzers, and primary diagnosis were also considered. A
significant correlation was found for time on dialysis (P < 0.001),
hematocrit (P < 0.001), ferritin (P < 0.05), PTH (P < 0.001) and
aluminum (P < 0.05). The highest correlation coefficients were found
for time on dialysis (latex: N = 126, r = 0.50, P < 0.001; zymosan: N
= 126, r = 0.58, P < 0.001). Multivariate correlation analysis of one
clinical parameter together with time on dialysis to PMNL response
showed that the correlation was strongly weakened or disappeared for
ferritin, aluminum and PTH, but not for hematocrit. Our data indicate
that time since the start of dialysis is an important, but not unique
factor, influencing polymorphonuclear functional capacity in a hemodi-
alysis population.
Infections are a major source of morbidity and mortality in
end-stage renal disease [1—3]. In the host defense against
bacterial infection, a critical role is played by polymorphonu-
clear cells, which destroy ingested bacteria by the production of
oxygen free radicals during the respiratory burst [4—8]. Having
been struck by the considerable scatter that could be observed
in the results of functional studies of phagocytosis in uremia,
and by the lack of literature data explaining this, the present
study was undertaken to clarify this aspect. Although manifold
observational studies convincingly demonstrate a defect of the
phagocytic system in uremia [9], no attempts have been made to
clarify the role of the contributing factors, although there are
many potential candidates. The present correlation study, en-
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closing multiple independent factors, is as far as we know one
of the first studies trying to answer this question.
In a previous study, we demonstrated that polymorphonu-
clear hexose monophosphate shunt (HMS)-response, registered
as the C02-production from glucose metabolism by the HMS,
was defective both in non-dialyzed and dialyzed uremic patients
[10]. The changes in glucose metabolism by the HMS were
related to the incidence of infection and septicemia [101.
Various factors, such as the time since the start of dialysis,
aluminum, hematocrit, and parameters of dialysis adequacy are
possibly related to alterations of immune defense. Other factors
such as iron stores [11], serum parathormone [12] and phospho-
rus [13], and dialyzer membrane bioincompatibility [10, 14, 15],
have been claimed to affect functional aspects of the immune
defense. However, their relation to HMS-related C02-produc-
tion in response to respiratory burst has not yet been evaluated.
Since many of these factors may influence one another, their
intermutual relation should be also considered.
In the present study, on a database of 126 observations in
hemodialysis patients, polymorphonuclear C02-production by
the HMS in response to particle challenge is correlated with 14
quantitative and three qualitative parameters by individual and
multivanate analysis, to disclose possible connections between
these individual factors and phagocytosis.
Methods
Patient population
The study was performed in a population of 126 patients,
mean age 63.2 1.0 years, 78 males and 48 females. Their
primary diagnoses were: chronic interstitial nephritis (CIN; N
= 65), chronic glomerulonephritis (CGN; N = 38), renal vas-
cular disease (N = 20), other (N = 3). Renal diagnoses were
documented from the clinical history, the aspect of the urinary
sediment, the presence or absence of proteinuria, the radiologic
and echographic aspect of the kidneys. In most cases renal
biopsy was performed, unless history, imaging of the kidneys
and aspect of the urine all pointed in the direction of tubuloin-
terstitial disease.
Exclusion criteria were: diabetes, history of malignancy,
hematologic or liver disease, and active infection within the last
two months before investigation, as illustrated by hospitaliza-
tion and/or fever >38°C. Patients on drugs such as antibiotics,
cytostatics or corticosteroids were also excluded from evalua-
tion. The patients were all on maintenance hemodialysis, on a
regular dialysis schedule, three times weekly. Dialysis dose was
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administered and adapted according to the current rules of urea
kinetic modeling [16, 17]. Dialysis was performed with a pres-
sure-pressure single-cannula system, as previously described
[18].
The patients were on the same membrane and with the same
dialytic prescription during at least one month preceding the
study. However, different patients were treated with different
membranes and some of them were on reused dialyzers.
As dialysis membranes were used: cuprophane Bravo 501
(Belico, Mirandola, Italy; N = 36) and Gambro GF-l20 (Lund,
Sweden; N = 56), and low-flux and high-flux polysulfone (F6
and F60, Fresenius, Bad Hamburg, Germany) as dialyzers with
a synthetic membrane (N = 34). The reuse was only performed
on the capillary Gambro GF-120 dialyzers (N = 56) and
consisted of sterilization with formaldehyde 4%, in an auto-
mated procedure with quality control [19]. All dialyses were
performed against bicarbonate dialysate without addition of
glucose. All blood samples for study were obtained on Monday
pre-dialysis, at the time of the monthly biochemical control.
Methods of evaluation
Polymorphonuclear HMS-response to stimuli was assessed
as described previously [10, 20, 21]. In brief, we measured
'4C02-production by PMNL's from radiolabeled glucose by the
hexose monophosphate shunt, as an index of the quantity of
energy delivered to NAD(P)H-oxidase, in the production of
oxygen free radical species. The measurements were performed
on 50 l of whole blood, collected before dialysis. The blood
samples were incubated with 10 d glucose-l-'4C (0.5 g/10 ,td).
The sample was evaluated in the resting state, without addition
of stimuli, or after the addition of polystyrene latex beads (0.8
/Lm) or zymosan (5 mg/l00 ml) to the samples.
During incubation at 37°C for one hour, '4C02 was trapped on
a filter containing 100 d I M NaOH, and counted in 2 ml
Permablend in a Packard liquid scintillation counter (tri-carb
3385, Packard Instruments Co., Warrenville, Illinois, USA).
Analysis was done in quadruplicate and expressed as disinte-
grations per minute (DPM).
Total leukocyte numbers and differentiation were obtained by
standard flow cytometric counting methods. The resting value
was subtracted from the value after stimulation with latex and
zymosan (delta latex and delta zymosan). The results were
obtained as absolute values (disintegrations/min per ml) or as
normalized values for polymorph counts measured by standard
flow cytometric counting methods (disintegrations/min per
1,000 PMNL). As these methods of expression gave compara-
ble information, only the normalized values will be shown.
Besides parameters of polymorphonuclear HMS function, we
registered per patient the following indices: time on dialysis,
age, sex, dialyzer membrane type, primary disease, residual
endogenous creati, le clearance, hematocrit, serum albumin,
creatinine, phosphrus and ferritin. Biochemical determina-
tions occurred according to standard procedures. Residual
clearance was calculated from pre- and post-dialysis serum
creatinine determinations, and a 44-hour interdialytic urine
collection.
Intact parathormone levels were measured in 93 patients by
the Allegro immunoradiometnc assay (Nichols Institute, San
Juan C pistano, California, USA). Aluminum levels were eval-
uated 115 patients by atomic-absorption spectrophotometry,
baseline and 48 hours after the administration in the arterio-
venous fistula of 1,000 mg desferrioxamine (Desferral') at the
end of the previous hemodialysis session.
Dialyzer membranes were divided in bioincompatible (cu-
prophane) and biocompatible (synthetic dialyzers and reused
cuprophane) regarding their effect on complement and leuko-
cyte activation [14, 15, 22].
In 114 patients, dialysis adequacy was estimated by determi-
nation of the relation between total clearance over distribution
volume of urea (KtIV), protein catabolic rate (PCR) and time
averaged urea concentration (TACurea) [16, 17].
In view of the correlation that was found between PMNL
HMS-response and time since the start of dialysis, we under-
took a prospective study in nine patients (5 males, 4 females,
mean age 52 9 years), in whom PMNL-function was followed
from the start of dialysis, up to the 18th month of treatment.
Five patients were on capillary cuprophane, and four on low
flux polysulphone (F6), and the same treatment strategy was
maintained during the entire protocol. Blood samples for the
evaluation of PMNL-C02-production were collected immedi-
ately before the start of the first dialysis, and pre-dialysis at
week 3, and at months 3, 6, 12, and 18.
Statistical analysis
All statistical tests were performed with the Statgraphics'
package. Results are expressed as means SEM. Different
patient groups were compared first by variance analysis
(ANOVA), and when statistical significance was reached, data
were further submitted to analysis for unpaired values (Mann-
Whitney U test). The data from the prospective study were
submitted to a paired analysis. Single regression among indi-
vidual parameters was obtained by Pearson's test. To exclude
intermutual influences, multivariate regression towards phago-
cytic function parameters and time on dialysis was performed
for all parameters. For those parameters where statistical
significance was reached, a multistep procedure was per-
formed, to evaluate whether those parameters significantly
contributed to the model. In this manner, that is, by testing
multiple different combinations, the best fitting combination of
parameters with PMNL function was constructed.
Statistical significance was accepted for P < 0.05.
Results
The results (mean SEM, median and range) obtained for the
numerical parameters under study in the overall patient popu-
lation are summarized in Table 1. Polymorph hexose mono-
phosphate shunt activity in response to phagocytic challenge
was lower in the patient group as compared to normal controls
(N = 126 and 50, respectively, latex: 69.6 2.9 vs. 154.2 7.2;
zymosan: 163.0 6.9 vs. 339.3 15.4 DPM/l03 PMNL; P <
0.01).
The results of the linear correlation-regression analysis of the
individual parameters with indices of phagocytic C02-produc-
tion are illustrated in Table 2. Both for the response to latex and
to zymosan, the most significant correlation was found with
time on dialysis (P < io; r = 0.50 for latex and 0.58 for
zymosan; Fig. I).
Further parameters showing significant correlation with poly-
morphonuclear HMS-related C02-production were parathor-
mone (both for latex and zymosan), ferritin, baseline aluminum
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Mean SEM Median Range
Delta CO2 latex
DPM/103 PMNL
69.6 2.9 66.6 1.3—162.8
Delta CO2 zymosan 163.0 6.9 149.8 22.0—531.4
DPM/103 PMNL
Time on dialysis 1086.1 110.3 670.5 12.4—6269.7
days
Hematocrit % 25.1 0,5 24.1 15.9—41.0
Serum creatjnjne 10.9 0.3 10.9 4.3—18.5
mg/100 ml
Serum phosphorus 5.1 0.1 5.2 1.7—11.2
mg/100 ml
Serum ferritin 218.3 21.0 147.5 8.3—1170.6
mg/100 ml
Serum albumin 3.8 0.1 3.8 2.3—4.9
mg/100 ml
PTH pg/mi 182.4 28.9 90.1 9.4—1855.0
Aluminum 1 pg/mi 27.5 2.3 20.5 1.2—136.1
Aluminum 2pg/ml 72.1 5.5 60.8 6.0—275.0
Ccrml/mifl 1.3 0.1 1.1 0.0—6.7
PCR 1.0 0.1 1.0 0.6—1.6
g/kg body wt 24 h
TACurca glliter 50.5 1.2 50.3 26.0—87.0
KtN 1.0 0.1 0.9 0.5—1.8
Age years 63.1 1.1 65.0 23.0—83.0
Time on dialysis days
Hematocrit %
Serum creatinine
mg/lOO ml
Serum phosphorus
mg/lOO ml
Serum ferritin
mg/100 ml
Serum albumin
mg/100 ml
PTH pg/mi
Aluminum 1 pg/mi
Aluminum 2 pg/mI
Ccr mi/mm
PCR
g/kg body wi 24 hr
TACurra g/liter
Kt/V
Age years
Prob. is probability
Table I.
a < ,o5
and aluminum after desferrioxamine (only for latex; note that
the correlations were weak) and hematocrit (only for zymosan;
Table 2).
Since no significant correlation with PMNL C02-production
was found for Kt/V, we considered separately the length of the
dialysis treatment (in hours), but this also gave no significant
correlation (N = 126; latex: r = 0.05, P > 0.05; zymosan: r =
0.11, P > 0.05).
Serum creatinine, phosphorus, PTH, residual creatinine
clearance, Kt/V, aluminum and age were correlated with time
on dialysis (Table 3).
For each parameter the patient population was divided in two
subgroups according to the median value, and a comparison
was made of phagocytic function and time on dialysis. A
difference in polymorphonuclear response was found for time
on dialysis (P < 0.001), hematocrit (P < 0.05, only for zymosan)
and aluminum (P < 0.01; Fig. 2), but not for the other
parameters. Division based upon serum creatinine (P < 0.05),
residual creatinine clearance (P < 0.01), age (P < 0.01) and
serum aluminum (P < 0.01), disclosed a difference in time on
dialysis (Fig. 3).
The results of the multivariate regression analyses of poly-
morphonuclear glucose break-down and time on dialysis with
the other individual factors are illustrated in Table 4.
Significant correlations observed in the single regression
analysis remained present in the multivariate approach for
serum hematocrit and serum PTH, but only in the response to
zymosan, and for PTH at markedly lower significance levels
than in the single regression analysis. For aluminum, the
significance that was present at individual correlation-regres-
sion analysis versus time on dialysis disappeared when multi-
factorial regression including both time on dialysis and alumi-
num together was applied. Both for PTH and serum aluminum,
these data suggest that the significant correlation with phago-
cytosis in the single regression analysis, may partly depend
upon their own relation to time on dialysis.
However, a weak inversed correlation appeared for zymosan
versus serum creatinine, and phosphorus, that was not ob-
r served for single regression analysis. This suggests that the
inversed correlation between serum creatinine/phosphorus and
polymorphonuclear HMS activity is neutralized by the positive
correlation between serum creatinine/phosphorus and time on
dialysis.
Table 1. Summary statistics for the numerical parameters
Abbreviations are: PMNL, polymorphonuclear leukoctyes; PTH,
parathormone; aluminum 1, baseline serum aluminum; aluminum 2,
serum aluminum after administration of desferrioxamine; Ccr, residual
endogenous creatinine clearance; PCR, protein catabolic rate; TACurea,
time averaged urea concentration (1 week) (BUN); Kt/V, ratio of total
dialyzer urea clearance over distribution volume.
Table 2. Single correlations of PMNL CO2 production by HMS with
the other numerical parameters under study
z CO2 latex
DPMIIO3 PMNL
Prob. r
CO2 zymosan
DPM/103 PMNL
<io
0.62
0.67
0.500a
<0.100
<0.100
Prob.
0.99
0.575a
<0.100
0.65 <0.100 0.72 <0.100
0.01
0.03
0.02
0.31
0.22
0.265a
0.200a
0.200a
<0.100
<0.100
0.20 0.100
0.35 <0.100
0.47 <0.100
level; other abbreviations
The best fitting model for the scatter of PMNL function after
0.04 0. 173 o.64 <0.100 stimulation with zymosan was constructed with time on dialy-
sis, hematocrit, PTH and serum creatinine (r = 0.671; Table 5).
0.42 <0.100 0.30 <0.100 This suggests that all these parameters significantly contribute
<l0- 0 458 to the distribution of PMNL function. The strongest influence,
0.35 <0.100 however, was due to time on dialysis. For latex, the best fitting
0.16 0.141 model is constructed with time on dialysis only (coefficient:
0.60 <0.100 0.01345, F-remove: 34.6074, r = 0.529).
0.65 <0.100 Finally, no difference in C02-production or time on dialysis
089 <0.100 was found when the group was divided according to the
16 0.141 non-numeric parameters of sex, biocompatibility of dialyzers,
0.68 <0.100 and primary diagnosis. Considering the patients using first use
and reused cuprophane separately also indicated no significant
differences.
A prospective study was undertaken in nine patients in view
of the correlation between time since the start of dialysis and
PMNL-function, and in view of the possibility that these results
were the consequence of patient selection, those patients with
better PMNL-function surviving longer. The results of this
study are illustrated in Figure 4. An initial decrease in func-
tional capacity, with a nadir at week 3, was observed. Then,
are the same as in
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Fig. 1. Correlation-regression analysis
between polymorphonuclear hexose
monophosphate response (expressed as DPM/
1O PMNL) and time since the start of
dialysis (days*Hl?). Y = a + bX [X: time on
dialysis, Y: CO2 production in response to
latex (A) or zymosan (B)]. Response to latex(N = 126, a = 55.24, b = 0.0132, r =
0 2 4 6 8 0.498168, P < 0.001) and zymosan (N = 126,
a = 123.73, b = 0.0372, r = 0.575125, P <
Time on dialysis, daysxlcF 0.001).
function gradually improved, and, compared to the start of
dialysis, significantly higher values were reached at the end of
the 12th to the 18th follow-up month. Note that the values at the
start were at 70% below the normal range.
Discussion
In this study, polymorphonuclear HMS activity in response
to challenging stimuli is correlated to parameters of patient
status, to formulate mechanisms interfering with PMNL func-
tion in ESRD. A defect is demonstrated in the respiratory burst
response in a substantial number of the patients involved. The
most relevant result is a positive correlation to time since the
start of dialysis, with a nadir of PMNL activity early after the
start of hemodialysis (Figs. 1 and 4). PMNL functional capacity
improved by 45.5% for the response to latex and by 34.1% for
zymosan in patients >670 days on dialysis (Fig. 2). After more
than 10 years, the response was twice as high than at the start
of dialysis, close to the values obtained in healthy subjects.
These results are relevant in the understanding of the suscep-
tibility to infection of the dialyzed uremic patient, as infection
and septicemia remain among the major causes of morbidity
and mortality in this population [1—3]. A relation between
C
0
E
F
I-1*
-I **
I I I I I
0 20 40 60 80 100
ACO2-production
DPM/1000PMNL
Fig. 2. Response in hexose monophosphate shunt activity (DPM/1U3
PMNL) to challenge with latex (above) and zymosan (below) with the
patient group divided according to the median value of various param-
eters. Differences are found for A and B: time since start dialysis <and
>670 days; C and D: hematocrit < and > 24.1%;E and F: aluminum <
and > 20.5 pg/mI. * P < 0.05; ** P < 0.01; *** P < 0.001.
polymorphonuclear activity, and the development of infection
and septicemia necessitating hospitalization was demonstrated
earlier [10]. Conform with a higher infection risk early after the
start of dialysis, Nsouli et at showed in a follow-up study over
more than 10 years in a group of 191 patients with positive blood
-jz
a-0
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Table 3. Single correlation of time on dialysis with other parameters
under study
Time on dialysis
Prob. r
Hematocrit % 0.64 <0.100
Serum creatinine mg/lOO ml 0.002 0.265a
Serum phosphorus mg/100 ml 0.04 0. l73
Serum ferritin mg/100 ml 0.18 0.100
Serum albumin mg/100 ml 0.95 <0.100
PTH pg/mi <i0 0.4l2a
Aluminum 1 pg/mi 0.002 0.283a
Aluminum 2 pg/mi <l0 0.436a
Ccr mi/mm 0.003 0.265a
PCR g/24 hr 0.98 <0.100
TACurea g/iiter 0.53 <0.100
Kt/V 0.005 0.245a
Age years 0.02 0.224a
A Latex
A
B
C
0
E I**
F
0 40 50 60 70 80
B Zymosan
A
B
Abbreviations are the same as in Tables 1 and 2.
a <0.05
212 Vanholder et a!: Phagocytosis in HD
-4
-I **
I **
0 400 800 1200
Fig. 3. Time since start on dialysis with the patient group divided
according to the median value of various parameters. Differences are
found for A and B: serum creatinine < and> 10.9 mgIlOO ml; C and D:
creatinine clearance (residual) < and> 1.1 mllmin; E and F: age <and
> 65 years; G and H: aluminum <and > 20.5 pg/mI. * P < 0.05; ** P
<0.01; *** P < 0.001.
Table 4. Multivariate regression with PMNL function as dependent
variable and time on dialysis and each parameter under study as
independent variables
CO2 latex
DPM/103 PMNL
Prob. T-value
1 CO2 zymosan
DPM/103 PMNL
T-value Prob.
Hematocrit % 0.40 —0.85 <iO 3.84
Serum creatinine mg/lOU ml 0.21 —1.25 0.03 —2.19
Serum phosphorus mgIIOO ml 0.50 —0.66 0.05 —1.92
Serum ferritin mg/IOU ml 0.12 1.55 0.71 —0.37
Serum albumin mg/lOU ml 0.37 0.90 0.22 —1.23
PTH pg/mi 0.50 0,67 0.01 2.86
Aluminum 1 pg/mi 0.36 0.92 0.65 —0.44
Serum aluminum 2 pg/mi 0.79 0.27 0.50 —0.67
Ccr mI/mm 0.66 0.43 0.21 1.26
PCRg/24 hr 0.19 —1.32 0.57 0.57
TACr00g/liter 0.06 —1.92 0.76 0.31
Kt/V 0.60 —0.51 0.82 —0.22
Age years 0.59 0.54 0.24 1.18
T-values and probabilities (Prob.) are obtained with analysis of
variance for the multivariate model, with PMNL function as dependent
variable and time on dialysis and one of the other numeric parameters
as independent variables. Abbreviations are the same as in Table 1
through 3.
< 0.05
cultures that respectively 25 and 69% of the septic episodes
occurred within the first month and the first year of dialysis [23].
Older literature data conform with this diminished immune
functional capacity early after the start of dialysis [13, 24].
Our results are helpful in the planning of support of the
immune system in the most vulnerable period, which is situated
during the first weeks after the start of dialysis. We could
recently demonstrate an improvement of phagocytosis: (1) in
parallel with the rise in hematocrit during EPO-treatment [25];
(2) during treatment with the third generation cephalosporin
cefodizime [21, 26]. Administration of these compounds could
be of potential help in improving early morbidity and mortality.
Table 5. Stepwise selection of best fitting model in correlation with
response to zymosan
Independent
variable Coefficient sa t-value P
Time on dialysis
Hematocrit
Parathormone
Creatinine
0.002
0.155
0.003
—0.273
<0.001
0.068
0.001
0.113
5.88
2.27
2.27
—2.42
<0.0001
0.0260
0.0259
0.0177
Time since start of dialysis, days
Fig. 4. Prospective evaluation (N =9) of PMNL functional capacity in
response to latex (below) and zymosan (above). Evolution in a compact
group over a period of 1.5 years. Time point 0 is before the start of the
first dialysis. * F < 0.05 vs. start of dialysis; 0 p < 0.05 vs. nadir in
PMNL function (week 3).
Thus, their application should especially be considered in the
weeks immediately following the start of dialysis.
The first weeks of dialysis are further characterized by a fall
in PMNL functional capacity [10], as well as by an acute and a
chronic decrease in circulating PMNL number [22] during
dialysis with complement activating dialyzers. The use of these
dialyzers should thus be discouraged, especially in the period
immediately following the start of dialysis, both in patients with
acute and with chronic renal failure.
Also in function of these differences, the time since the start
of dialysis should be taken into account in studies of immune
function in dialyzed populations. Our observation may explain
why in some studies no suppression of polymorphonuclear
function is observed [27, 28].
We can only speculate about the mechanisms involved in this
change in function with progression of time. It may be attrib-
uted to the slow removal from the intracellular compartment of
a toxic factor(s), probably with a higher molecular weight
and/or a different kinetic behavior, compared to the small water
soluble compounds, that are currently used in the follow-up of
dialysis adequacy 129].
Second, a number of compensatory mechanisms may be
developed, counterbalancing the original depression of the
immune system. Remarkably enough, comparative analysis of
patient groups by Herbelin et al showed a rise in post-dialysis
interleukin- 1 production that was only observed in chronic
maintenance dialysis patients, and not at the first dialysis [30].
These data suggest a gradual and progressive triggering of the
immune response as a consequence of recurrent acute-phase
stimulation.
Finally, the gradual improvement of PMNL activity over
A 1*
B
C
D
E
F
G
H
I I I Ll_ I I
r = 0.656 (93 observations fitted).
Time since start of dialysis, days
200
1600 o
2 100
on-
0
0 100 200 300 400 500 600
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time may be attributed to patient selection, with those patients
with better function surviving longer. However, in a long-term
prospective study on the same patients without dropouts (N =
9), we could demonstrate an increment of polymorphonuclear
function over time (Fig. 4), reducing the likelihood of patient
selection.
In addition to time on dialysis, several other parameters were
evaluated. Among those hematocrit, serum ferritin, PTH and
aluminum were also correlated to polymorphonuclear function.
The relation to hematocrit may be attributed to better oxygen
transport and metabolic status. To conform with this, a better
immune and/or phagocyte response was found in patients
treated with erythropoietin [25, 31, 32]. Correlation in this study
was significant only for zymosan. The stimulation with zymo-
san requires more oxygen in the immediate surroundings of the
PMNL than latex, so the delivery of oxygen by the circulation
may become a rate limiting factor especially with zymosan.
According to our data, there is a positive correlation between
PTH and PMNL function. PTH per se is highly dependent on
time on dialysis (P < 0.01, Table 3). Altough Tuma et al
attributed an increase in resting state chemiluminescence pro-
duction to PTH [33], it is more generally accepted that PTH
decreases the response of challenged PMNL [34]. Therefore,
PTH conceivably is mainly related to time on dialysis per se.
Aluminum levels in this study are correlated with polymorph
function, in contrast to data reported by Koda et al [35]. The
correlation here disappears, however, upon multivariate anal-
ysis together with time on dialysis (Table 4). Finally, the
present, albeit weak, positive correlation between PMNL func-
tion and serum creatinine/phosphorus at multivariate regres-
sion, may be an index of the positive influence of a better
metabolic status on immune function; likewise, Lowrie and
Lew observed a positive correlation between serum creatinine
and survival on dialysis, low serum creatine being associated
with high death risk [36].
In conclusion, our results indicate that PMNL function is
strongly and positively correlated to time on dialysis and
hematocrit. Furthermore, serum parathormone, ferritin and
aluminum are correlated with PMNL function, but these pa-
rameters are also correlated with time on dialysis. These effects
should be considered in clinical, therapeutic, and experimental
conditions of evaluation of the polymorph immune defense
system in end-stage renal disease.
Reprint requests to R. Vanholder, M.D., Nephrology Department,
University Hospital, De Pintelaan 185, B9000, Ghent, Belgium.
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